Adenovirus armed with bispecific T cell activator

Inventors

Champion, Brian • BROMLEY, Alice Claire Noel

Assignees

Akamis Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11840702-B2

Patent

Publication Date

2023-12-12

Expiration Date


Abstract

An adenovirus comprising a sequence of formula (I) 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein BY comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.

Core Innovation

The invention relates to an adenovirus comprising a sequence of formula (I) with defined adenoviral genome architecture. The formula (I) specifies E1A/E1B, an E2B-L1-L2-L3-E2A-L4 region, E3, a region comprising a restriction site and/or one or more transgenes, L5, and E4, together with 5′ ITR and 3′ ITR and, in some descriptions, defined adenoviral regions B1, BA, B2, X, BB, BY, and B3.

A central component is a transgene cassette comprising four transgenes encoding a FAP-bispecific T cell activator, CXCL10, CXCL9, and IFNα. The FAP-bispecific T cell activator corresponds to an anti-CD3/anti-FAP configuration, and the transgenes are provided as shown in SEQ ID NO: 95 or as a polynucleotide encoding the same amino acid sequence.

The disclosure supports cancer treatment using pharmaceutical compositions comprising the adenovirus. The described concept includes piggybacked targeted delivery to cancer/stroma, local secretion of a short half-life engager, and a two-pronged mechanism combining oncolysis and T-cell activation while reducing off-target effects.

Claims Coverage

The provided material includes one independent claim focused on a defined adenovirus with a four-transgene cassette. The claim coverage centers on the formula (I) genome architecture and the inserted cassette encoding a FAP-bispecific T cell activator, CXCL10, CXCL9, and IFNα, with dependent claims adding further sequence references, replication competence, capsid components, and therapeutic use.

Adenovirus defined by formula (I) genome architecture

An adenovirus comprising a sequence of formula (I) in which the genetic elements comprise E1A/E1B, E2B-L1-L2-L3-E2A-L4, E3, a region comprising a restriction site and/or one or more transgenes, L5, and E4.

Four-transgene cassette encoding FAP-bispecific T cell activator, CXCL10, CXCL9, and IFNα

The adenovirus of formula (I) includes a transgene cassette comprising four transgenes encoding a FAP-bispecific T cell activator, CXCL10, CXCL9, and IFNα as shown in SEQ ID NO: 95 or a polynucleotide encoding the same amino acid sequence.

Transgene cassette fixed to SEQ ID NO: 95

The adenovirus wherein the transgene cassette comprises a polynucleotide sequence shown in SEQ ID NO: 95.

Inclusion of SEQ ID NO: 84

The adenovirus defined as including SEQ ID NO: 84.

Replication competent adenovirus

The adenovirus that is replication competent.

Hexon and fibre derived from Ad11

The adenovirus that includes a hexon and a fibre derived from Ad11.

Treatment of epithelial-origin cancer by administering the adenovirus

A method of treating a patient with epithelial-origin cancer by administering the adenovirus or a related pharmaceutical composition.

Overall, the claims focus on an adenovirus defined by formula (I) carrying a transgene cassette with four transgenes encoding a FAP-bispecific T cell activator, CXCL10, CXCL9, and IFNα (SEQ ID NO: 95 or a polynucleotide encoding the same amino acid sequence), with further narrowing by sequence references, replication competence, defined capsid components, and use for treating epithelial-origin cancers.

Stated Advantages

FAP-bispecific T cell activator-expressing recombinant adenoviruses induce T-cell activation and tumor-target lysis.

The kinetics of tumor lysis are influenced by promoter choice.

Endogenous tumor-associated lymphocytes are activated and autologous FAP+ cells are depleted in malignant ascites/pleural effusion exudate fluids and patient material.

Modulation of TGFβ and partial PD-1/PD-L1 checkpoint effects are described.

TAM polarization toward a more activated phenotype is described.

Measurable transgene secretion and T-cell marker upregulation are described for additional EnAd variants.

Piggybacked targeted delivery to cancer/stroma.

Local secretion of a short half-life engager.

Two-pronged oncolysis and T-cell activation.

Reduced off-target effects.

Documented Applications

Malignant ascites and pleural effusion exudate fluids.

Patient material.

Ex vivo prostate tumor slice cultures.

Treatment of epithelial-origin cancers.

Treating a patient with epithelial-origin cancer by administering the adenovirus or a pharmaceutical composition including the adenovirus.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.